Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Divi's Laboratories (DIVI IN)
Watchlist
125
Analysis
Health Care
•
India
Divi's Laboratories Ltd. manufactures pharmaceutical products which include generic drugs and their intermediates. The Company also undertakes contract research activities for other pharmaceutical companies.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Nykaa
•
02 Jul 2025 22:31
Nykaa Block - US$140m Selldown by Banga Family
Harindarpal Singh Banga, one of Nykaa’s early investors, aims to raise around US$140m via selling a stake of around 2.1% at a floor price of around...
Akshat Shah
Follow
618 Views
Share
bearish
•
Knowledge Realty Trust
•
19 Jun 2025 13:15
Knowledge Realty Trust Pre-IPO - The Negatives - Not All Assets Have Been Doing Well
Knowledge Realty Trust (KRT) is planning to raise about US$558m through its upcoming India IPO. In this note, we talk about the not-so-positive...
Akshat Shah
Follow
521 Views
Share
bullish
•
Divi's Laboratories
•
12 Jun 2025 23:13
Divi's Laboratories (DIVI IN): Double-Digit Growth and Margin Improvement to Continue
Divi's Laboratories finished FY25 strong. Moving ahead, the company is looking to maintain double-digit revenue growth. This compares favorably...
Tina Banerjee
Follow
771 Views
Share
bearish
•
Sagility
•
26 May 2025 22:46
Sagility India IPO Lockup - US$1.5bn Lockup Release; PE Promoter Will Have to Trim for Free-Float
Sagility B.V. plans to offload up to 15.02% stake in Sagility India via block deals worth INR26.7bn (US$314.7m). The secondary share sale is priced...
Akshat Shah
Follow
1.1k Views
Share
bullish
•
Schloss Bangalore Ltd
•
26 May 2025 10:40
Schloss Bangalore IPO - Thoughts on Peer Comp and Valuation
Schloss Bangalore Limited is looking to raise about US$400m in its upcoming India IPO. The deal has been downsized from an earlier size of US$600m....
Akshat Shah
Follow
704 Views
Share
First
Previous
9
10
11
12
13
14
15
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x